サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1662119

メラノーマ治療薬の世界市場

Melanoma Therapeutics

出版日
ページ情報
英文 162 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
メラノーマ治療薬の世界市場
出版日: 2025年02月26日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 162 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

メラノーマ治療薬の世界市場は2030年までに95億米ドルに達する

2024年に44億米ドルと推定されるメラノーマ治療薬の世界市場は、分析期間2024-2030年にCAGR 13.7％で成長し、2030年には95億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである皮膚メラノーマ治療薬は、CAGR 13.7％を記録し、分析期間終了時には43億米ドルに達すると予測されています。眼メラノーマ治療薬セグメントの成長率は、分析期間でCAGR 14.6％と推定されます。

米国市場は12億米ドルと推定、中国はCAGR 18.6％で成長予測

米国のメラノーマ治療薬市場は、2024年に12億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに22億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは18.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.8%と11.2%と予測されています。欧州では、ドイツがCAGR 10.6%で成長すると予測されています。

メラノーマ治療薬- 主要動向と促進要因

メラノーマ治療薬は、最も侵攻性の高い皮膚がんであるメラノーマの治療に焦点を当てた、腫瘍学の重要かつ急速な発展を遂げている分野です。メラノーマは、皮膚の色素産生を担う細胞であるメラノサイトから発生し、体の他の部位に素早く転移することで有名です。良好な転帰を得るためには早期発見と治療が重要であり、治療戦略の進歩により生存率は著しく向上しています。歴史的には、治療の選択肢は手術、放射線療法、化学療法に限られており、その成功の程度はさまざまで、しばしば重篤な副作用を伴っていました。しかし、この10年間で、標的療法と免疫療法の登場により、黒色腫治療のパラダイムシフトが起こった。これらの革新的なアプローチは、治療の状況を一変させ、患者により効果的で個別化された治療の選択肢を提供するようになった。

標的治療は、メラノーマに関連する特定の遺伝子変異に焦点を当てることで、メラノーマ治療に革命をもたらしました。例えば、メラノーマ症例の約50％に存在するBRAF遺伝子の変異は、ベムラフェニブやダブラフェニブのようなBRAF阻害剤で標的とすることができます。これらの薬剤は、トラメチニブやコビメチニブなどのMEK阻害剤と併用されることが多く、健康な組織を温存しながらがん細胞を特異的に攻撃することで、患者の予後が大幅に改善することが示されています。ペムブロリズマブ（キイトルーダ）やニボルマブ（オプジーボ）のようなチェックポイント阻害剤は、メラノーマ細胞に対する身体の免疫反応を強化します。これらの治療法は顕著な有効性を示し、一部の患者では長期にわたる寛解に至っています。さらに、複数の治療法の長所を活用する併用療法の開発は、治療効果をさらに高め、耐性メカニズムを克服することを約束する新たな動向です。

メラノーマ治療薬市場の成長は、いくつかの要因によって牽引されています。第一に、メラノーマの罹患率の増加は、紫外線曝露の増加や診断方法の改善も一因となっており、効果的な治療に対する需要が高まっています。第二に、ゲノミクスと分子生物学の技術的進歩により、新規治療標的の同定が容易になり、新薬の開発が加速しています。第三に、免疫療法や標的治療の承認と成功が研究開発への多額の投資を促し、競争的で革新的な市場環境を育んでいます。さらに、臨床試験の拡大と画期的治療薬に対する規制当局の支援により、承認プロセスが合理化され、新治療がより迅速に市場に投入されるようになった。患者やヘルスケア提供者が、遺伝子プロファイリングに基づいてオーダーメイドの治療計画を提供する個別化医療をますます好むようになっているため、消費者行動も一役買っています。最後に、メラノーマに罹患しやすい人口の高齢化と、早期発見・早期治療の重要性に対する意識の高まりが、市場の持続的成長に寄与しています。これらの要因が、メラノーマ治療薬市場の堅調な拡大と継続的な技術革新を後押ししています。

セグメント

タイプ（皮膚黒色腫、眼黒色腫、粘膜黒色腫）;セラピー（免疫療法、標的療法、化学療法、放射線療法、外科手術）

調査対象企業の例（全14件）

  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Iovance Biotherapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6303

Global Melanoma Therapeutics Market to Reach US$9.5 Billion by 2030

The global market for Melanoma Therapeutics estimated at US$4.4 Billion in the year 2024, is expected to reach US$9.5 Billion by 2030, growing at a CAGR of 13.7% over the analysis period 2024-2030. Cutaneous Melanoma Therapeutics, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Ocular Melanoma Therapeutics segment is estimated at 14.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 18.6% CAGR

The Melanoma Therapeutics market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 18.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.8% and 11.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Melanoma Therapeutics - Key Trends and Drivers

Melanoma therapeutics represent a critical and rapidly evolving segment of oncology, focused on treating melanoma, the most aggressive form of skin cancer. Melanoma arises from melanocytes, the cells responsible for pigment production in the skin, and is notorious for its ability to metastasize quickly to other parts of the body. Early detection and treatment are crucial for favorable outcomes, and advances in therapeutic strategies have significantly improved survival rates. Historically, treatment options were limited to surgery, radiation therapy, and chemotherapy, which had varying degrees of success and often came with severe side effects. However, the last decade has witnessed a paradigm shift in melanoma treatment, driven by the advent of targeted therapies and immunotherapies. These innovative approaches have transformed the therapeutic landscape, offering more effective and personalized treatment options for patients.

Targeted therapies have revolutionized melanoma treatment by focusing on specific genetic mutations associated with the disease. For instance, mutations in the BRAF gene, present in approximately 50% of melanoma cases, can be targeted with BRAF inhibitors like vemurafenib and dabrafenib. These drugs, often used in combination with MEK inhibitors such as trametinib and cobimetinib, have shown substantial improvements in patient outcomes by specifically attacking cancer cells while sparing healthy tissue. Immunotherapy has further propelled the field forward, with checkpoint inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo) enhancing the body's immune response against melanoma cells. These therapies have demonstrated remarkable efficacy, leading to long-lasting remissions in some patients. Additionally, the development of combination therapies, which leverage the strengths of multiple treatment modalities, is an emerging trend that promises to further enhance therapeutic efficacy and overcome resistance mechanisms.

The growth in the melanoma therapeutics market is driven by several factors. Firstly, the increasing incidence of melanoma, partly due to greater UV exposure and better diagnostic practices, has heightened the demand for effective treatments. Secondly, technological advancements in genomics and molecular biology have facilitated the identification of novel therapeutic targets, accelerating the development of new drugs. Thirdly, the approval and success of immunotherapies and targeted therapies have spurred significant investment in research and development, fostering a competitive and innovative market environment. Additionally the expansions of clinical trials and regulatory support for breakthrough therapies have streamlined the approval process, bringing new treatments to market more rapidly. Consumer behavior also plays a role, as patients and healthcare providers increasingly prefer personalized medicine approaches that offer tailored treatment plans based on genetic profiling. Lastly, the aging population, which is more susceptible to melanoma, and the increasing awareness about the importance of early detection and treatment contribute to sustained market growth. These factors collectively drive the robust expansion and continuous innovation within the melanoma therapeutics market.

SCOPE OF STUDY:

The report analyzes the Melanoma Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Cutaneous Melanoma, Ocular Melanoma, Mucosal Melanoma); Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Surgery)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 14 Featured) -

  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Iovance Biotherapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Melanoma Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Melanoma Propels Demand for Innovative Therapeutics
    • Advances in Genomics and Molecular Biology Expand Addressable Market Opportunity
    • Breakthrough Immunotherapies Spur Growth in Melanoma Treatment Options
    • Approval of Targeted Therapies Strengthens Business Case for Personalized Medicine
    • Increasing UV Exposure and Its Impact on Melanoma Rates Throws the Spotlight on Preventive Measures
    • Consumer Shift towards Personalized Medicine Accelerates Adoption of Genetic Profiling
    • Aging Population Sustains Growth in Melanoma Therapeutics Market
    • Technological Innovations in Drug Delivery Enhance Efficacy and Patient Compliance
    • Combination Therapies Propel Market Growth by Overcoming Resistance Mechanisms
    • Increasing Awareness Campaigns for Skin Cancer Prevention and Early Detection Generate Demand
    • Development of Biosimilars and Their Impact on Market Dynamics
    • Emerging Markets for Companion Diagnostics Enhance Personalized Treatment Approaches
    • Economic Growth in Developing Regions Expands Market Potential for Melanoma Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Melanoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Melanoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Melanoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Melanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cutaneous Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cutaneous Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Cutaneous Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Ocular Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Ocular Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Ocular Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mucosal Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mucosal Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Mucosal Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • JAPAN
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • CHINA
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • EUROPE
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Melanoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Melanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • FRANCE
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • GERMANY
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Melanoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Melanoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Melanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • INDIA
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Melanoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Melanoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Melanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Melanoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Melanoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Melanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030
  • AFRICA
    • Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2015, 2025 & 2030

IV. COMPETITION